A study of gedatolisib for first-line advanced breast cancer
Part of Cancer, Skin clinical trials.
This trial tests a new targeted therapy called gedatolisib for people with HR-positive, HER2-negative advanced breast cancer who have not yet received treatment for metastatic disease. It aims to see if adding this drug to standard hormone therapy can help control the cancer longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have HR-positive, HER2-negative breast cancer that has spread or cannot be removed by surgery and is advanced.
- You are an adult (male or female) and if you are a woman who can still have children, you must have a negative pregnancy test and use effective birth control during the study and for 2 years after.
- Your cancer got worse while on or within 12 months of finishing hormone therapy after initial treatment, or you have not had prior systemic therapy for advanced breast cancer.
- You must have tumor tissue or a blood sample available for testing a gene called PIK3CA.
- You have at least one tumor that can be measured on scans (measurable disease) and your overall health is good enough for daily activities (ECOG score 0-2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a new immunotherapy drug (adebrelimab) with a targeted pill (dalpiciclib) and standard hormone therapy for women with advanced hormone receptor positive, HER2 negative breast cancer. It may help patients who have not yet had certain prior treatments, aiming to slow the cancer's growth.
This trial tests if adding a targeted drug (CDK4/6 inhibitor) to hormone therapy works better than hormone therapy alone for women with a certain type of breast cancer (HR+/HER2-). The study measures the activity of tumor cells (Ki-67) to help decide treatment.
This Phase 2 study tests a “precision platform” approach—treatment before surgery—based on specific test results from your breast tumor. It may help determine whether the treatment plan works better for people with particular breast cancer subtypes and healthy organ function.
This trial tests a new treatment (GDC-4198) alone or with another drug (giredestrant) compared to a standard combination (abemaciclib and giredestrant) for people with advanced hormone receptor-positive, HER2-negative breast cancer that has progressed after previous treatments.
This trial tests a combination of three targeted drugs for a type of advanced breast cancer that is both ER-positive and HER2-positive. The goal is to see if adding these two new drugs to standard hormone therapy can help shrink or control the cancer.
This trial tests a new study medicine (PF-07248144) combined with fulvestrant in people with a certain type of advanced breast cancer (HR-positive, HER2-negative) that has worsened after previous treatments. It may be an option if you've already tried a CDK4/6 inhibitor and endocrine therapy.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.